autologous cd8+ slc45a2-specific t lymphocytes

Autologous CD8+ SLC45A2-specific T lymphocytes are a personalized cell therapy product consisting of a patient’s own (autologous) CD8+ T cells that have been isolated and expanded ex vivo to specifically recognize the melanoma-associated antigen SLC45A2. SLC45A2 is a melanocyte differentiation antigen with high tumor selectivity and minimal expression in normal tissues, making it an attractive target for immunotherapy in melanoma, particularly uveal melanoma. The therapy involves collecting peripheral blood mononuclear cells from patients who are HLA-A*02:01 or HLA-A*24:02 positive, stimulating and expanding the SLC45A2-specific CD8+ T cell population using peptide-pulsed dendritic cells and cytokines (such as IL-21), then reinfusing these expanded cytotoxic T lymphocytes back into the patient. This adoptive cell transfer aims to enhance anti-tumor immune responses by directly targeting tumor cells expressing SLC45A2 while minimizing off-target toxicity. Clinical trials have evaluated this approach in combination with conditioning regimens (e.g., cyclophosphamide), interleukin-2 support, and checkpoint blockade (ipilimumab) for metastatic uveal melanoma[1][4][5][6][7][8].

Other names

autologous cd8+ slc45a2-specific t lymphocytesautologous cd8+ slc45a2 t cells